CoChat

Changes in Albumin Excretion in the Diabetes Prevention Program

Open access
Diabetes Prevention Program Research Group · 2009 · Diabetes Care

The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.

Abstract

OBJECTIVE: Increased urinary albumin excretion rates have been linked to nephropathy and macrovascular disease. We here describe the baseline prevalence and effect of Diabetes Prevention Program (DPP) interventions on the development and reversal of elevated albumin excretion. RESEARCH DESIGN AND METHODS: Urine albumin-to-creatinine ratios (ACRs) were calculated from untimed urine collections. Analyses compared participants by treatment group, diabetes and hypertension status, and use of ACE inhibitors or angiotensin II receptor blockers (ARBs). RESULTS: Elevated ACR levels (≥30 mg/g creatinine) were present at baseline in 198 (6.2%) of 3,188 participants: placebo 5.3%, metformin 6.5%, and intensive lifestyle (ILS) 6.8%. Of the 2,802 with ACR measurements at baseline and at the end of the study, the percentage with elevated levels declined (incident and regression) from 6.2 to 6.1%, with no significant differences between the groups even with adjustment for ACE inhibitor and ARB use. The odds of developing an elevated ACR were 59% higher for a participant who developed diabetes compared with one who did not. CONCLUSIONS: At entry into the DPP, an elevated ACR was present in 6.2%. Despite the marked decrease in progression to diabetes and the improvement in insulin resistance and other cardiovascular risk markers in the ILS and metformin groups, there was no improvement in ACR, on average, in those two groups. However, the frequency of an elevated ACR was higher in participants who developed diabetes. An increased ACR may have multiple causes, thus obscuring the improvements that might have been expected with the reduction in insulin resistance seen in the DPP.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2337/dc08-1400

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Prevalence of elevated ACR levels at baseline by subgroups. The height of the bars represents the percentage of subjects with an elevated ACR (≥30 mg/g), ■ represents microalbuminuria (ACR between 30 and <300), and □ represents macroalbuminuria (ACR ≥300). The prevalence of albuminuria differed among subgroups for age, race/ethnicity, SBP, DBP, and BMI (P < 0.05).
Figure 1 Prevalence of elevated ACR levels at baseline by subgroups. The height of the bars represents the percentage of subjects with an elevated ACR (≥30 mg/g), ■ represents microalbuminuria (ACR between 30 and <300), and □ represents macroalbuminuria (ACR ≥300). The prevalence of albuminuria differed among subgroups for age, race/ethnicity, SBP, DBP, and BMI (P < 0.05).CC BY-NC-ND · PubMed Central
Figure 2 Prevalence of elevated ACR (≥30 mg/g) at end of study by treatment group and diabetes (DM) status. P value indicates the difference in rates between the diabetic and nondiabetic treatment groups.
Figure 2 Prevalence of elevated ACR (≥30 mg/g) at end of study by treatment group and diabetes (DM) status. P value indicates the difference in rates between the diabetic and nondiabetic treatment groups.CC BY-NC-ND · PubMed Central
Figure 3 Median ACR (milligrams per gram) by diabetes (DM) and hypertension status at end of study.
Figure 3 Median ACR (milligrams per gram) by diabetes (DM) and hypertension status at end of study.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 30 references

Cited by

See all 26

Metadata

Authors
Diabetes Prevention Program Research Group
Corresponding author
Diabetes Prevention Program Research Group
Venue
Diabetes Care
Published
2009-01-08
Volume
32
Issue
4
Pages
720-725
ISSN
  • 0149-5992 (ISSN-L)
  • 1935-5548
OpenAlex
W1543666374
Cited by
26
References
30
Citations by year
2025: 2 · 2024: 1 · 2023: 3 · 2021: 2 · 2020: 2 · 2019: 1 · 2018: 1 · 2017: 1 · 2016: 2 · 2015: 3 · 2012: 3
FWCI
1.84
Type
journal article
Language
en
Open access
Locations
  • Diabetes Care (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Funders
  • American Diabetes Association
  • Bristol-Myers Squibb
  • National Institutes of Health
  • Centers for Disease Control and Prevention
  • National Institute on Aging
  • National Institute of Diabetes and Digestive and Kidney Diseases (U01DK048489)
  • National Institute of Child Health and Human Development
  • National Center on Minority Health and Health Disparities
  • National Center for Research Resources
  • National Institute on Minority Health and Health Disparities
  • Office of Women's Health
Topics
  • Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
Keywords
albumin-creatinine ratio, albuminuria, diabetic nephropathy, Diabetes Prevention Program, metformin, intensive lifestyle intervention, diabetes prevention, hypertension, ACE inhibitors, angiotensin receptor blockers, insulin resistance, macroangiopathy
MeSH terms
Adult, Aged, Albuminuria, Creatinine, Diabetes Mellitus, Diabetic Nephropathies, Female, Humans, Hypoglycemic Agents, Life Style, Metformin, Middle Aged, Reference Values, Vascular Diseases, Washington, Prevalence, Patient Selection

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.